Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Celldex Therapeutics, Inc. Director's Dealing 2024

Jun 17, 2024

31801_dirs_2024-06-17_9ebaa0d6-8ae3-443d-ac5e-e3dcbd4f142a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2024-06-13

Reporting Person: MARINO JAMES J (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-06-13 Non-Qualified Stock Option (right to buy) $36.43 A 16500 Acquired 2034-06-13 Common Stock (16500) Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.